PubMed · 15837623
Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas.
Abstract
To predict the prognosis of neuroblastoma patients and choose a better therapeutic protocol, we developed a cDNA microarray carrying 5340 genes obtained from primary neuroblastomas and examined 136 tumor samples. We made a probabilistic output statistical classifier that provided a high accuracy in prognosis prediction (89% at 5 years) and a highly reliable method to validate it. Kaplan-Meier analysis indicated that the patients in an intermediate group defined by existing markers are divided by microarray into two further groups with 5 year survivals for 36% and 89% of patients (p < 10(-4)), i.e., with unfavorably and favorably predicted neuroblastomas, respectively. According to these results, we developed a gene subset chip for a clinical tool, for which our classifier exhibited 88% prediction accuracy.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Miki Ohira, Shigeyuki Oba, Yohko Nakamura, Eriko Isogai, Setsuko Kaneko, Atsuko Nakagawa, Takahiro Hirata, Hiroyuki Kubo, Takeshi Goto, Saichi Yamada, Yasuko Yoshida, Misa Fuchioka, Shin Ishii, Akira Nakagawara. 2005. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas.. https://doi.org/10.1016/j.ccr.2005.03.019
Cite the original work for its findings. Save a collection to share your selection of sources.